Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
Open Access
- 1 September 2015
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Applied Immunohistochemistry & Molecular Morphology
- Vol. 23 (8), 541-549
- https://doi.org/10.1097/pai.0000000000000256
Abstract
Supplemental Digital Content is available in the text.Keywords
This publication has 18 references indexed in Scilit:
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- Programmed death-ligand 1 (PD-L1) expression in various tumor typesJournal for ImmunoTherapy of Cancer, 2013
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the LungClinical Lung Cancer, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- A TALE nuclease architecture for efficient genome editingNature Biotechnology, 2010
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationMedical Oncology, 2010
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004
- Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000